New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

The next phase of Kilroy's big Oyster Point project is seeing interest from tech and financial services as well as biotech, long the dominant industry in South San Francisco.

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as ...

In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...